New research is adding a fresh layer to the puzzle of pancreatic cancer, pointing to meaningful differences in how tumors can behave across patient groups. A University of Cincinnati team examined tumor samples and immune activity in patients from different racial backgrounds and found patterns that may help explain why this disease can look and act differently from one person to another.
The study looked at 22 pancreatic tumors from patients around the United States, including seven Black patients and 15 non-African American patients. Instead of finding one simple biological answer, the researchers saw a mix of differences in cancer cell makeup and the immune environment wrapped around the tumors.
One of the more striking findings was that tumors from Black patients had fewer of the most common pancreatic cancer cells and more cells with mixed traits. Some of those intermediate cell states have been linked to drug resistance in other settings, but this study did not prove they changed treatment results in these patients.
The immune side of the story was just as interesting. Tumors from Black patients also showed more B cells and bigger clusters of immune cells, and the researchers spotted signs that some of those B cells may actually dampen the body’s fight against cancer. That matters because pancreatic cancer has long been known as a tough disease to push back with immune-based treatment.
Dr. Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute, said pancreatic cancer can be especially slippery because the tumor does not just sit there passively. It can shape the immune system around it, turning the body’s defenses into something more helpful to the cancer than to the patient.
That kind of immune sabotage helps explain why immunotherapy has been far less successful in pancreatic cancer than in some other cancers. The cancer itself is only part of the picture, and the tissue surrounding it can change how the disease grows, spreads, and responds to treatment.
Importantly, the researchers did not find major differences in the key genetic mutations that usually drive the disease. That suggests the story is bigger than DNA alone and that the tumor microenvironment may play a heavier role than many people expect.
Pancreatic cancer is also about 20% more likely to develop in Black Americans than in non-African Americans, according to the study’s background data. That gap does not have a single obvious explanation, which is exactly why studies like this draw attention from oncologists and researchers alike.
Lead author Nina Steele, an assistant professor in UC’s College of Medicine, said the work shows why diverse participation in medical research matters. If studies leave out certain populations, important blind spots can linger, and those gaps can slow down the push toward treatments that work better for everyone.
Wadlow said patients can have tumors that share the same broad mutations but still behave very differently once the surrounding immune cells and tissue are taken into account. That variation may also show up across patient populations, making one-size-fits-all treatment plans feel less and less convincing.
Even with the promising clues, the researchers were careful not to oversell the results. They have not yet shown whether the tumor differences affect survival, or whether the mixed-cell populations respond differently to standard chemotherapy.
There are also other pieces still missing from the puzzle. The team needs tissue from people without cancer to better understand when these differences begin, and larger studies will be needed before anyone can say how much the findings should change care.
Wadlow also noted that race and ancestry do not tell the whole story. Environmental factors, social conditions, and biology can all pile up in ways that make cancer research messy, and that messiness is exactly why broader, better-designed trials matter.
For newly diagnosed patients, one practical point stands out: hereditary genetic testing can still be useful. If an inherited mutation is found, family members may be able to get tested too, which can open the door to earlier attention and more informed decisions.
The bigger takeaway is that pancreatic cancer is not a single, tidy disease sitting neatly inside a lab report. It is a shifting, stubborn illness shaped by cells, immune signals, and the body around it, and the next wave of research will need to keep those layers in view.
